183 related articles for article (PubMed ID: 16643206)
21. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.
Núñez M; Soriano V
Drug Saf; 2005; 28(1):53-66. PubMed ID: 15649105
[TBL] [Abstract][Full Text] [Related]
22. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.
Núñez M
J Hepatol; 2006; 44(1 Suppl):S132-9. PubMed ID: 16364487
[TBL] [Abstract][Full Text] [Related]
23. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
Bonacini M
Clin Infect Dis; 2004 Mar; 38 Suppl 2():S104-8. PubMed ID: 14986282
[TBL] [Abstract][Full Text] [Related]
24. Hepatotoxicity of antiretroviral therapy.
Kontorinis N; Dieterich D
AIDS Rev; 2003; 5(1):36-43. PubMed ID: 12875106
[TBL] [Abstract][Full Text] [Related]
25. [Hepatotoxicity of coinfected patients].
Bessone F; Belloso W; Schroder T
Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S43-5; discussion S74-82. PubMed ID: 16862858
[No Abstract] [Full Text] [Related]
26. Incidence of hepatotoxicity of highly active antiretroviral therapy in a tertiary health centre in Nigeria.
Ugiagbe RA; Malu AO; Bojuwoye BJ; Onunu AN
Niger Postgrad Med J; 2012 Sep; 19(3):127-32. PubMed ID: 23064166
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
28. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
Cooper CL; Mills E
Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217
[TBL] [Abstract][Full Text] [Related]
29. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
30. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management.
Manfredi R
AIDS; 2003 Oct; 17(15):2253-6. PubMed ID: 14523283
[No Abstract] [Full Text] [Related]
31. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis.
Akhtar MA; Mathieson K; Arey B; Post J; Prevette R; Hillier A; Patel P; Ram LJ; Van Thiel DH; Nadir A
Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1194-204. PubMed ID: 18989143
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
[TBL] [Abstract][Full Text] [Related]
33. Managing antiretroviral-associated liver disease.
Dieterich D
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S34-9. PubMed ID: 14562856
[TBL] [Abstract][Full Text] [Related]
34. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
Stone SF; Lee S; Keane NM; Price P; French MA
J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
[TBL] [Abstract][Full Text] [Related]
35. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
Mankhatitham W; Lueangniyomkul A; Manosuthi W
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
[TBL] [Abstract][Full Text] [Related]
36. Hepatic safety and HAART.
McGovern B
J Int Assoc Physicians AIDS Care (Chic); 2004 Nov; 3 Suppl 2():S24-40. PubMed ID: 15673131
[No Abstract] [Full Text] [Related]
37. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).
Savès M; Vandentorren S; Daucourt V; Marimoutou C; Dupon M; Couzigou P; Bernard N; Mercié P; Dabis F
AIDS; 1999 Dec; 13(17):F115-21. PubMed ID: 10597772
[TBL] [Abstract][Full Text] [Related]
38. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
[TBL] [Abstract][Full Text] [Related]
39. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.
Sulkowski MS
Semin Liver Dis; 2003 May; 23(2):183-94. PubMed ID: 12800071
[TBL] [Abstract][Full Text] [Related]
40. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
Crane HM; Van Rompaey SE; Kitahata MM
AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
